Your browser doesn't support javascript.
loading
Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers.
Halleran, J L; Callahan, B J; Jacob, M E; Sylvester, H J; Prange, T; Papich, M G; Foster, D M.
Affiliation
  • Halleran JL; Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA. jlhaller@ncsu.edu.
  • Callahan BJ; Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
  • Jacob ME; Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
  • Sylvester HJ; Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
  • Prange T; Department of Clinical Sciences, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
  • Papich MG; Deparment of Biomedical Sciences, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
  • Foster DM; Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, NC, USA.
Sci Rep ; 11(1): 11249, 2021 05 27.
Article in En | MEDLINE | ID: mdl-34045586
ABSTRACT
Fluoroquinolones are a class of antimicrobial commonly used in human medicine, and deemed critical by the World Health Organization. Nonetheless, two formulations are approved for the treatment of respiratory disease in beef cattle. The objective of this study was to determine the gastrointestinal pharmacokinetics and impact on enteric bacteria of cattle when receiving one of the two dosing regimens (high 40 mg/kg SC once or low 20 mg/kg IM q48hr) of danofloxacin, a commonly utilized synthetic fluoroquinolone in veterinary medicine. Danofloxacin was administered to 12 steers (age 7 months) fitted with intestinal ultrafiltration devices at two different dosing regimens to assess the gastrointestinal pharmacokinetics, the shifts in the gastrointestinal microbiome and the development of resistant bacterial isolates. Our results demonstrated high intestinal penetration of danofloxacin for both dosing groups, as well as, significant differences in MIC values for E. coli and Enterococcus between dosing groups at selected time points over a 38 day period. Danofloxacin treatment consistently resulted in the Euryarchaeota phyla decreasing over time, specifically due to a decrease in Methanobrevibacter. Although microbiome differences were minor between dosing groups, the low dose group had a higher number of isolates with MIC values high enough to cause clinically relevant resistance. This information would help guide veterinarians as to appropriate dosing schemes to minimize the spread of antimicrobial resistance.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enterococcus / Fluoroquinolones / Gastrointestinal Tract / Escherichia coli / Gastrointestinal Microbiome / Anti-Bacterial Agents Limits: Animals Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enterococcus / Fluoroquinolones / Gastrointestinal Tract / Escherichia coli / Gastrointestinal Microbiome / Anti-Bacterial Agents Limits: Animals Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: United States